US-based Cardurion Pharmaceuticals has completed enrolment in two multi-centre, global Phase II CYCLE trials of the orally-administered phosphodiesterase 9 (PDE9) inhibitor, CRD-750, targeting both ...

A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

Early symptoms like fatigue, breathlessness, swelling mimic common heart issues, causing cardiac amyloidosis to go undetected ...

An anti-hazing network honors a UVA leader, the American Heart Association lauds UVA Health for heart and stroke care, and ...